Hansoh Pharmaceutical
Hansoh Pharmaceutical Group Company Limited, commonly known as Hansoh Pharmaceutical, is a leading biopharmaceutical enterprise headquartered in China (CN). Founded in 1995, the company has established a strong presence in major operational regions, including Asia and beyond, focusing on the research, development, manufacturing, and marketing of innovative medicines. Specialising in oncology, central nervous system disorders, and autoimmune diseases, Hansoh Pharmaceutical is recognised for its commitment to high-quality products and cutting-edge therapies. The company has achieved significant milestones, including the successful launch of several proprietary drugs that have garnered attention in both domestic and international markets. With a robust pipeline and a dedication to advancing healthcare, Hansoh Pharmaceutical has positioned itself as a key player in the biopharmaceutical industry, earning accolades for its contributions to medical science and patient care.
DitchCarbon Score
How does Hansoh Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hansoh Pharmaceutical's score of 17 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Hansoh Pharmaceutical's reported carbon emissions
In 2023, Hansoh Pharmaceutical reported total carbon emissions of approximately 92,112,060 kg CO2e, comprising 10,546,850 kg CO2e from Scope 1 and 81,565,210 kg CO2e from Scope 2. Additionally, Scope 3 emissions were recorded at about 51,543,360 kg CO2e. This data reflects a commitment to reducing greenhouse gas emissions, with a target to decrease the intensity of emissions from Scope 1 and 2 by 15% from 2021 levels by 2030. In 2021, the company’s emissions were approximately 122,328,000 kg CO2e, indicating a focus on improving sustainability practices. Hansoh Pharmaceutical has set a long-term goal of achieving carbon neutrality by 2060, encompassing all scopes of emissions. This commitment aligns with industry standards for climate action and reflects a proactive approach to environmental responsibility.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | 36,839,000 | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 2 | 92,421,000 | 00,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | 000,000 | - | - | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hansoh Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
